30 results
Thumbnail

D2.207 - Early serum IL-6 induction and delayed IL-17A suppression characterise wasp venom allergen-specific immunotherapy

Thumbnail

D2.196 - Elucidating the Immunological Mechanisms of Pollen Immunotherapy in Treating Food Allergy in Patients with Pollen-Food Allergy Syndrome

Thumbnail

D2.197 - Dose-Dependent Immunogenicity and Toxicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy

Thumbnail

D2.198 - Allergen identification and characterization of lysine modification in monomeric allergoid of Olea europea pollen extract

Thumbnail

D2.200 - An interim analysis of a multiCenter study on the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders (CALM study)

Thumbnail

D2.202 - Evaluation of Telemedicine Use in Dietary Advancement Therapy of Cow’s Milk and Egg Allergy: A Retrospective Study

Thumbnail

D2.204 - Allergic potential of plant-derived oils: in vitro murine model of allergies

Thumbnail

D2.205 - Profilin Allergy: Study of the Efficacy and Safety of an Immunotherapy Protocol for the Treatment of Profilin-Related Oral Allergy Syndrome

Thumbnail

D2.206 - Successful treatment of LTP syndrome using allergen immunotherapy: a clinical case

Thumbnail

D2.209 - 'Which bee was it?': A literature review of Honeybee Venom Immunotherapy used in paediatric patients stung by different bee subspecies

Thumbnail

D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies

Thumbnail

D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection

Thumbnail

D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper

Thumbnail

D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials

Thumbnail

D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps

Thumbnail

D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use

Thumbnail

D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study

Thumbnail

D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD

Thumbnail

D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?

Thumbnail

D2.457 - Hypersensitivity reactions for Enzyme Replacement Therapy in a Patient with Hunter syndrome